Background Image

Technological advances in health and medicine are creating unprecedented opportunity to dramatically improve human and animal health. From novel vaccine approaches to innovative medical devices, technological breakthroughs are key to mitigating outbreaks of emergent diseases or slowing the progress of chronic and degenerative diseases. At SMI, we are committed to helping biotechnology companies secure non-dilutive funds to advance the development of technologies in preparation for commercialization.   

  • Capabilities

    • Federal marketing strategy
    • Shaping funding opportunities
    • Prepositioning for competitive awards
    • Technical proposal shaping and editing
    • Expert guidance from former government officials
    • FDA guidance
    • Identifying teaming partners in industry and academia
    • Identifying funding opportunities
    • Provide federal marketing training sessions

  • Case Studies
  • Team

    SMI’s Life Sciences team is comprised of PhD-level scientists with extensive experience in securing federal funds for a wide range of technology development projects. We served as technical experts for a range of federal agencies including NIH, DTRA, BARDA, FEMA, DHS, and CDC, gaining valuable insights into how the government shapes and funds programs in technology development. SMI’s technical staff is supplemented by a team of former high level government officials familiar with the FDA regulatory process, DOD procurement, and federal policy initiatives. The Life Sciences team works in close coordination with SMI’s lobbyists in securing Congressional support for technology development and funding.

    SMI Team: Glen T. Mandigo

    Glen T. Mandigo

    President & CEO
    SMI Team: Bill McCann

    Bill McCann

    Chief Operating Officer
    SMI Team: Dr. Drew Ronneberg

    Dr. Drew Ronneberg

    Vice President
    SMI Team: Dr. David Visi

    Dr. David Visi

    SMI Team: Pat Malloy

    Pat Malloy

    SMI Team: Dennis Padilla

    Dennis Padilla

    Senior Contracting Specialist

  • Advisors

    Douglas Freitag

    20 years of experience with federal business development and market research

    John Frazier Glenn, Ph.D.

    Principal Asst. Research and Technology at the Army Medical Research and Materiel Command

    Robert "Bob" Johns

    Global Director of New Business for advanced technologies at Dow Corning Corporation

    Cynthia Kelley

    Advisor for countermeasures at the FDA's Center for Biologics Evaluation and Research

    Alan Liss, Ph.D.

    Directed the Public Health and Security Action Team Program at FDA

    Gerald Quinnan, Jr., M.D.

    Senior executive in the FDA and the DOD medical school

    C. Matthew Sagely

    25+ years of senior Washington leadership spanning several issue areas

    Gina Schatteman, Ph.D.

    Technical writer, academic researcher, and member of 25+ biomedical grant review panels

    James Tegnelia, Ph.D.

    Director of the DTRA and VP of DOD Programs at Sandia National Labs

    Anthony "Tony" Tether, Ph.D.

    Director of the Defense Advanced Research Projects Agency from 2001 through 2009